We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-6.97%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.62B
AUM Growth
-$52.9M
Cap. Flow
+$108M
Cap. Flow %
4.11%
Top 10 Hldgs %
34.14%
Holding
89
New
20
Increased
21
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$86.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$43M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.7M
4
ABBV icon
AbbVie
ABBV
+$37.6M
5
VEEV icon
Veeva Systems
VEEV
+$37.2M

Top Sells

Rank Stock Value
1
OM icon
Outset Medical
OM
+$128M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$34.1M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.4M
4
HRTX icon
Heron Therapeutics
HRTX
+$20.1M
5
HCA icon
HCA Healthcare
HCA
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.59%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
26
AstraZeneca
AZN
$269B
$38.1M 1.45%
288,400
+62,250
+28% +$8.17M
ABBV icon
27
AbbVie
ABBV
$465B
$37.7M 1.44%
+246,235
New +$37.6M
CI icon
28
Cigna
CI
$78.4B
$37.2M 1.42%
141,300
+47,165
+50% +$12.2M
MCK icon
29
McKesson
MCK
$104B
$34.5M 1.32%
105,811
– –
ICLR icon
30
Icon
ICLR
$13.7B
$34.3M 1.31%
158,183
– –
BIIB icon
31
CALL
Biogen
BIIB
$30.9B
$34M 1.3%
+166,800
New +$34.1M
TMO icon
32
Thermo Fisher Scientific
TMO
$214B
$33.8M 1.29%
62,143
– –
CAH icon
33
Cardinal Health
CAH
$53.7B
$33.4M 1.28%
639,783
– –
ERAS icon
34
Erasca
ERAS
$6.15B
$32.8M 1.25%
5,881,382
+1,089,976
+23% +$7.13M
CRBU icon
35
Caribou Biosciences
CRBU
$146M
$32.6M 1.24%
6,000,000
+1,629,455
+37% +$12.5M
BDX icon
36
Becton Dickinson
BDX
$46.4B
$32.2M 1.23%
130,697
-30,836
-19% -$7.83M
EW icon
37
Edwards Lifesciences
EW
$49.4B
$32.2M 1.23%
338,155
– –
UHS icon
38
Universal Health Services
UHS
$10.2B
$32M 1.22%
317,411
-123,925
-28% -$15.5M
NVRO
39
DELISTED
NEVRO CORP.
NVRO
$28.9M 1.1%
659,410
+9,897
+2% +$544K
THC icon
40
Tenet Healthcare
THC
$22.2B
$28.6M 1.09%
544,583
– –
CTLT
41
DELISTED
CATALENT, INC.
CTLT
$23.4M 0.89%
218,366
-37,730
-15% -$3.84M
BCRX icon
42
BioCryst Pharmaceuticals
BCRX
$2.42B
$22.9M 0.87%
+2,162,411
New +$22.3M
PEN icon
43
Penumbra
PEN
$12.6B
$22.8M 0.87%
182,786
+16,067
+10% +$2.55M
MYGN icon
44
Myriad Genetics
MYGN
$476M
$21.4M 0.82%
1,177,250
-705,107
-37% -$14.6M
BAX icon
45
Baxter International
BAX
$12.8B
$20.8M 0.79%
+323,907
New +$23.5M
ELV icon
46
Elevance Health
ELV
$81.5B
$20.6M 0.79%
42,734
– –
GBIO
47
DELISTED
Generation Bio
GBIO
$18.2M 0.69%
277,331
+219,903
+383% +$14.4M
PMVP icon
48
PMV Pharmaceuticals
PMVP
$57.1M
$17.3M 0.66%
1,214,164
+767,864
+172% +$11.2M
KRTX
49
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$16.5M 0.63%
130,293
-76,823
-37% -$8.83M
ADAP
50
DELISTED
Adaptimmune Therapeutics
ADAP
$15.5M 0.59%
9,109,780
+6,735,106
+284% +$11.6M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2022 Portfolio in Review

As of Q2 2022, PFM Health Sciences held 89 positions worth $2.62B, down 2% from $2.67B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences deployed $108M of net new capital in Q2 2022, opening 20 new positions and adding to 21 existing holdings. Its largest new stake was Merck: 971,998 shares worth $88.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Syndax Pharmaceuticals, an estimated $24.4M trimmed.

  • PFM Health Sciences's largest Q2 2022 buy was Merck: 971,998 shares worth $88.6M.
  • PFM Health Sciences added most to uniQure in Q2 2022, an estimated $27.1M increase.
  • PFM Health Sciences's biggest Q2 2022 reduction was Syndax Pharmaceuticals, cutting an estimated $24.4M.
  • PFM Health Sciences fully exited Outset Medical in Q2 2022, selling an estimated $128M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $2.62B portfolio in Q2 2022.
  • PFM Health Sciences opened 20 new positions and closed 10 in Q2 2022.
  • PFM Health Sciences's portfolio value fell 2% quarter-over-quarter to $2.62B.

Based on PFM Health Sciences's 13F filing for Q2 2022, filed 15 Aug 2022.